viapharmaceuticals_13g-a1.htm - Generated by SEC Publisher for SEC Filing

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TMnPiwNXlsO1DbklRI/YVOiVhohE+AGY7RbIrarZXymvQYpZM/VrEDky7dQtHcQv G8k5huTQpDl8zhM7hrqsZg== 0000906344-09-000219.txt : 20090210 0000906344-09-000219.hdr.sgml : 20090210 20090210163637 ACCESSION NUMBER: 0000906344-09-000219 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090210 DATE AS OF CHANGE: 20090210 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: VIA Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001003929 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330687976 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-50201 FILM NUMBER: 09586191 BUSINESS ADDRESS: STREET 1: 750 BATTERY STREET STREET 2: SUITE 330 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 BUSINESS PHONE: 415-283-2200 MAIL ADDRESS: STREET 1: 750 BATTERY STREET STREET 2: SUITE 330 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 FORMER COMPANY: FORMER CONFORMED NAME: CORAUTUS GENETICS INC DATE OF NAME CHANGE: 20030206 FORMER COMPANY: FORMER CONFORMED NAME: GENSTAR THERAPEUTICS CORP DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: UROGEN CORP DATE OF NAME CHANGE: 19960508 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Enable Growth Partners L P CENTRAL INDEX KEY: 0001316907 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 1 FERRY BUILDING STREET 2: SUITE 255 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 BUSINESS PHONE: 415-677-1577 MAIL ADDRESS: STREET 1: 1 FERRY BUILDING STREET 2: SUITE 255 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 SC 13G/A 1 viapharmaceuticals_13g-a1.htm SCH 13G/A1 (02/10/09) viapharmaceuticals_13g-a1.htm - Generated by SEC Publisher for SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)

VIA Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock, $0.001 par value per share
(Title of Class of Securities)

92554T103
(CUSIP Number)

December 31, 2008
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

£ Rule 13d-1(b)

T Rule 13d-1(c)

£ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


1	.	Names of Reporting Persons.				ENABLE CAPITAL MANAGEMENT, LLC

2	.	Check the Appropriate Box if a Member of a Group (See Instructions)					(a) £
							(b) £
3	.	SEC Use Only

4	.	Citizenship or Place of Organization					DELAWARE

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH			5	.	Sole Voting Power		943,171

			6	.	Shared Voting Power		0

			7	.	Sole Dispositive Power		943,171

			8	.	Shared Dispositive Power		0

9	.	Aggregate Amount Beneficially Owned by Each Reporting Person					943,171

10	.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)					£

11	.	Percent of Class Represented by Amount in Row (9)					4.8	%

12	.	Type of Reporting Person (See Instructions)					OO


1	.	Names of Reporting Persons.				ENABLE GROWTH PARTNERS, L.P.

2	.	Check the Appropriate Box if a Member of a Group (See Instructions)					(a) £
							(b) £
3	.	SEC Use Only

4	.	Citizenship or Place of Organization					DELAWARE

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH			5	.	Sole Voting Power		0

			6	.	Shared Voting Power		883,006

			7	.	Sole Dispositive Power		0

			8	.	Shared Dispositive Power		883,006

9	.	Aggregate Amount Beneficially Owned by Each Reporting Person					883,006

10	.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)					£

11	.	Percent of Class Represented by Amount in Row (9)					4.5	%

12	.	Type of Reporting Person (See Instructions)					PN


1	.	Names of Reporting Persons.				MITCHELL S. LEVINE

2	.	Check the Appropriate Box if a Member of a Group (See Instructions)					(a) £
							(b) £
3	.	SEC Use Only

4	.	Citizenship or Place of Organization					UNITED STATES

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH			5	.	Sole Voting Power		943,171

			6	.	Shared Voting Power		0

			7	.	Sole Dispositive Power		943,171

			8	.	Shared Dispositive Power		0

9	.	Aggregate Amount Beneficially Owned by Each Reporting Person					943,171

10	.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)					£

11	.	Percent of Class Represented by Amount in Row (9)					4.8	%

12	.	Type of Reporting Person (See Instructions)					IN

Item 1(a). Name of Issuer:

VIA Pharmaceuticals, Inc.

Item 1(b). Address of Issuer’s Principal Executive Office:

750 Battery Street, Suite 330
San Francisco, CA 94111

Item 2(a). Name of Person Filing:

                  Enable Capital Management, LLC (“ECM”)
                  Enable Growth Partners, L.P. (“EGP”)
                  Mitchell S. Levine

Item 2(b). Address of Principal Business Office or, if none, Residence:

The business address of the reporting persons is One Ferry Building, Suite 255, San Francisco, CA 94111.

Item 2(c). Citizenship:

Reference is made to Item 4 of pages 2, 3 and 4 of this Schedule 13G (this “Schedule”), which Items are incorporated by reference herein.

Item 2(d). Title of Class of Securities:

Common Stock, $0.001 par value per share.

Item 2(e). CUSIP Number:

92554T103

Item 3. If this statement is filed pursuant to §§240.13d -1(b) or 240.13d -2(b) or (c), check whether the person filing is a:

£	(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
£	(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
£	(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
£	(d)	Investment company registered under section 8 of the Investment Company Act of
		1940 (15 U.S.C 80a-8).
£	(e)	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
£	(f)	An employee benefit plan or endowment fund in accordance with §240.13d-
		1(b)(1)(ii)(F);
£	(g)	A parent holding company or control person in accordance with § 240.13d-
		1(b)(1)(ii)(G);


£	(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act
		(12 U.S.C. 1813);

£	(i)	A church plan that is excluded from the definition of an investment company under
		section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

£	(j)	Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4. Ownership:

Reference is hereby made to Items 5-9 and 11 of pages 2, 3 and 4 of this Schedule, which Items are incorporated by reference herein.

The securities to which this Schedule relates (the “Securities”) are owned by certain investment limited partnerships, including EGP, and other client accounts, for which ECM serves as general partner and/or investment manager. ECM, as EGP’s and those other investment limited partnerships’ and client accounts’ general partner and/or investment manager, and Mitchell S. Levine, as managing member and majority owner of ECM, may therefore be deemed to beneficially own the Securities owned by EGP and such other investment limited partnerships and client accounts for the purposes of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Act 48;), insofar as they may be deemed to have the power to direct the voting or disposition of those Securities.

Neither the filing of this Schedule nor any of its contents shall be deemed to constitute an admission that ECM or Mr. Levine is, for any other purpose, the beneficial owner of any of the Securities, and each of ECM and Mr. Levine disclaims beneficial ownership as to the Securities, except to the extent of his or its pecuniary interests therein.

Under the definition of “beneficial ownership” in Rule 13d-3 under the Act, it is also possible that the individual general partners, executive officers, and members of the foregoing entities might be deemed the “beneficial owners” of some or all of the Securities insofar as they may be deemed to share the power to direct the voting or disposition of the Securities. Neither the filing of this Schedule nor any of its contents shall be deemed to constitute an admission that any of such individuals is, for any purpose, the beneficial owner of any of the Securities, and such beneficial ownership is expressly disclaimed.

The calculation of percentage of beneficial ownership in Item 11 of pages 2, 3 and 4 was derived from the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2008, in which the Issuer stated that the number of shares of its Common Stock outstanding as of November 10, 2008 was 19,739,968 shares.

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following X .

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

Not applicable.

Item 8. Identification and Classification of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable.

Item 10. Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 10, 2009	ENABLE CAPITAL MANAGEMENT, LLC

	By: /s/ Mitchell S. Levine
	Mitchell S. Levine, its Managing Member
	ENABLE GROWTH PARTNERS, L.P.
	By: Enable Capital Management, LLC, its General Partner
	By: /s/ Mitchell S. Levine
	Mitchell S. Levine, its Managing Member

	MITCHELL S. LEVINE

	/s/ Mitchell S. Levine
	Mitchell S. Levine

EXHIBITS LIST


Exhibit A	Joint Filing Undertaking	Page 9

EXHIBIT A

JOINT FILING UNDERTAKING

The undersigned, being authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule, as it may be amended, jointly on behalf of each of such parties.

Dated: February 10, 2009 ENABLE CAPITAL MANAGEMENT, LLC

By: /s/ Mitchell S. Levine

Mitchell S. Levine, its Managing Member

ENABLE GROWTH PARTNERS, L.P.

By: Enable Capital Management, LLC, its General Partner

By: /s/ Mitchell S. Levine

Mitchell S. Levine, its Managing Member

MITCHELL S. LEVINE

/s/ Mitchell S. Levine

Mitchell S. Levine

-----END PRIVACY-ENHANCED MESSAGE-----